Drug Approval | February 18, 2022
USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Dr. Raman has succeeded Victoria Richon
Virginia will be responsible for meeting client needs for both media and commercial analytics.
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Subscribe To Our Newsletter & Stay Updated
